Early Data Demonstrate Clinical Activity of Acalabrutinib in Difficult-to-Treat Chronic ...

(BUSINESS WIRE)-- AstraZeneca and its haematology Centre of Excellence, Acerta Pharma, today announced preliminary results from the Phase I/II ACE-CL-001 clinical trial of acalabrutinib in subsets of patients with two difficult-to-treat forms of chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.¹ The trial includes data from individuals with intolerance to ibrutinib and those with Richter transformation, when CLL transforms into a more aggressive lymphoma.² Findings were shared with the medical community during two oral presentations at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, USA. ...

Source : http://me-newswire.net//news/19175/en...